ReviewTranslational research : the journal of laboratory and clinical medicine2017
CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
Review in Translational research : the journal of laboratory and clinical medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.Frontiers in immunology · 2022Pooled it
- T-Cell Engagers in Lung Cancer: A Comprehensive Literature Review from Tarlatamab Approval to Next-Generation Strategies.Cancers · 2026Review
- Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future.International journal of molecular sciences · 2025Review
- [Modification with IL-21 and CCL19 enhances killing efficiency and tumor infiltration of NKP30 CAR-T cells in lung cancer].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Development of Personalized Strategies for Precisely Battling Malignant Melanoma.International journal of molecular sciences · 2024Review
- Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications.Cancer cell international · 2024Review
- Patient-Derived Microphysiological Systems for Precision Medicine.Advanced healthcare materials · 2024Review
- Immunological subtyping of salivary gland cancer identifies histological origin-specific tumor immune microenvironment.NPJ precision oncology · 2024Article
- Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment.Current pharmaceutical biotechnology · 2024Review
- CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks.Molecular cancer · 2023Review
- Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer.Translational lung cancer research · 2023Review
- Theranostic applications of selenium nanomedicines against lung cancer.Journal of nanobiotechnology · 2023Review
- Lung cancer immunotherapy: progress, pitfalls, and promises.Molecular cancer · 2023Review
- T lymphocyte cell: A pivotal player in lung cancer.Frontiers in immunology · 2023Review
- Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application.Frontiers in oncology · 2023Review
- The role of exosomal miR-181b in the crosstalk between NSCLC cells and tumor-associated macrophages.Genes & genomics · 2022Article
- CAR-T Cells for the Treatment of Lung Cancer.Life (Basel, Switzerland) · 2022Review
- CAR-T cell therapy for lung cancer: Potential and perspective.Thoracic cancer · 2022Review
- Review
- Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.Frontiers in immunology · 2022Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Immunotherapy is a promising field that harnesses the power of the immune system as a therapeutic agent for cancer treatment. Beneficial outcomes shown in patients with non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM) with relatively higher tumor-infiltrating T cells, combined with impressive responses obtained in a cohort of patients with NSCLC following checkpoint blockade therapy, lays a strong foundation to promote effector immune responses in these patients. One such approach being investigated is administration of tumor antigen-targeted T cells with transduction of a chimeric antigen receptor (CAR). CARs are synthetic receptors that enhance T-cell antitumor effector function and have gained momentum to investigate in solid tumors based on recent successes of clinical trials treating patients with B-cell hematologic malignancies. This review summarizes target antigens for CAR T-cell therapy that are being investigated in preclinical studies and clinical trials for both NSCLC and MPM patients. We discuss the rationale for combination immunotherapies for NSCLC and MPM patients. Additionally, we have highlighted the challenges and strategies for overcoming the obstacles facing translation of CAR T-cell therapy to solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.